SEC Form D · filed November 2, 2020
Dewpoint Therapeutics, Inc
Rule 506(b): private placement to accredited investors, no public advertising.
People & firms on this filing (20)
Anthony A. Hyman, Ph.D · Boston, MADirectorRichard A. Young, Ph.D · Boston, MADirectorAmeet A. Nathwani, M.D · Boston, MAExec · DirectorMark A. Murcko, Ph.D · Boston, MADirectorBruce H. Beutel · Boston, MAExecAmir H. Nashat · Boston, MAExec · DirectorJurgen A. Eckhardt, M.D · Boston, MADirectorSrinivas H. Akkaraju, M.D · Boston, MADirectorOliver H. Brandicourt, M.D · Boston, MADirectorGiuseeppe H. Ciaramella, Ph.D · Boston, MADirectorAnthony A. Hyman, Ph.D · Boston, MADirectorRichard A. Young, Ph.D · Boston, MADirectorAmeet A. Nathwani, M.D · Boston, MAExec · DirectorMark A. Murcko, Ph.D · Boston, MADirectorJurgen A. Eckhardt, M.D · Boston, MADirectorBruce H. Beutel · Boston, MAExecSrinivas H. Akkaraju, M.D · Boston, MADirectorOliver H. Brandicourt, M.D · Boston, MADirectorGiuseeppe H. Ciaramella, Ph.D · Boston, MADirectorAmir H. Nashat · Cambridge, MAExec · Director Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗